glp-1 research peptides Triple / GIP / Glucagon Receptor Agonist (CAS 2381089-83-2) GLP-1 Peptide UK | Research

Description

Limitations of Use: Saxenda and Victoza have the same active ingredient, liraglutide, and should not be used together or with other GLP-1 receptor agonist medicines It is not known if Saxenda is safe and effective when taken with other prescription, over-the-counter medicines, or herbal weight-loss products It is not known if Saxenda is safe and effective in children under 12 years of age It is not known if Saxenda is safe and effective in children aged 12 to 17 years with type 2 diabetes Who should not use S axenda

For travel, carry the medicine in a secure, dry place where the label remains readable

Cardiovascular and renal benefits have been consistently demonstrated, with lower rates of cardiovascular events observed in semaglutide-treated patients compared with placebo

Then for the second half of this ASM feature episode host, Dr Morgan Edwards, talks research and perioperative issues in anaesthesia with ASM international invited speaker, Prof Frances Chung